GF092
TRAIL蛋白，重组人类
Human TRAIL (TNF-Related Apoptosis Inducing Ligand), also called APO2 Ligand, is a cytotoxic protein which activates rapid apoptosis in tumor cells, but not in normal cells.
别名:
Apo2 Ligand
登录 查看组织和合同定价。
选择尺寸
关于此项目
UNSPSC Code:
12352202
NACRES:
NA.75
eCl@ss:
32160405
Form:
solid
Assay:
>98% (SDS-PAGE and HPLC)
Biological source:
human
Recombinant:
expressed in E. coli
Mol wt:
19.6 kDa
产品名称
TRAIL蛋白，重组人类, Human TRAIL (TNF-Related Apoptosis Inducing Ligand), also called APO2 Ligand, is a cytotoxic protein which activates rapid apoptosis in tumor cells, but not in normal cells.
biological source
human
recombinant
expressed in E. coli
assay
>98% (SDS-PAGE and HPLC)
form
solid
mol wt
19.6 kDa
manufacturer/tradename
Chemicon®
technique(s)
cell culture | mammalian: suitable
impurities
<0.1 ng/μg Endotoxin (of TRAIL/Apo2L; 1EU/μg)
input
sample type hematopoietic stem cell(s)
suitability
suitable for molecular biology
NCBI accession no.
UniProt accession no.
shipped in
dry ice
Quality Level
Gene Information
human ... TNFSF10(8743)
Application
人重组TRAIL 蛋白，可用作凋亡诱导剂：从各种细胞系中提取游离 DNA (cfDNA)配合 BV6 研究其在乳腺癌细胞系中的抗癌作用，研究其对乙醇诱导的干扰素表达对神经元中 TRAIL 释放的影响
Biochem/physiol Actions
TNF 相关凋亡诱导配体 (TRAIL) 可促进肿瘤细胞快速凋亡，同时保留正常细胞。TRAIL 的这种特性使其成为癌症治疗中的重要生物治疗剂。它通过与细胞膜上表达的两个死亡信号受体 DR4 和 DR5 结合来诱导细胞凋亡。
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
General description
研究领域：癌症TNF 相关凋亡诱导配体 (TRAIL) 是一种细胞毒性和 II 型膜蛋白。它属于肿瘤坏死因子 (TNF) 超家族。TRAIL 由各种免疫系统细胞表达，包括自然杀伤细胞、巨噬细胞、T 细胞和树突状细胞。人重组TRAIL 蛋白，是一种 19.6 kDa 蛋白
Physical form
无菌过滤，然后从 0.3 mg/mL（含 10mM 磷酸钠 + 110mM NaCl）溶液中冻干。
Preparation Note
冻干的蛋白可以在室温下保存数周，但最好在 -20°C 下保存。 快速离心后，在无菌水中重新配制至 0.5-1.0 mg/mL。 可以将该溶液稀释到其他缓冲溶液中，并在 4ºC 下保存 1 周或 -20ºC 以备将来使用。 自收到之日起，重悬的 GF092 应该以未稀释的等分试样在 -20°C 下保存长达 6 个月。应避免反复冻/融循环。
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
11 - Combustible Solids
wgk
WGK 3
The clinical trail of TRAIL
Duiker E W, et al.
European Journal of Cancer, 42(14), 2233-2240 (2006)
Frank A E Kruyt
Cancer letters, 263(1), 14-25 (2008-03-11)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors are promising targets for the selective eradication of tumor cells while sparing normal cells. Currently, both recombinant TRAIL proteins and TRAIL receptor agonistic antibodies are being tested in the clinic, showing encouraging antitumor
Brad A Davidson et al.
Communications biology, 7(1), 441-441 (2024-04-11)
Clinical circulating cell-free DNA (cfDNA) testing is now routine, however test accuracy remains limited. By understanding the life-cycle of cfDNA, we might identify opportunities to increase test performance. Here, we profile cfDNA release across a 24-cell line panel and utilize
Hong Wang et al.
Molecular cancer therapeutics, 19(12), 2585-2597 (2020-11-18)
Complexities in treating breast cancer with bone metastasis are enhanced by a vicious protumorigenic pathology, involving a shift in skeletal homeostasis toward aggressive osteoclast activity and polarization of immune cells supporting tumor growth and immunosuppression. Recent studies signify the role
Sahar Rafat et al.
Biology, 11(11) (2022-11-12)
Cancer is the utmost common disease-causing death worldwide, characterized by uncontrollable cell division with the potential of metastasis. Overexpression of the Inhibitors of Apoptosis proteins (IAPs) and autophagy correlates with tumorigenesis, therapeutic resistance, and reoccurrence after anticancer therapies. This study
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持